LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Tesaro, Inc. (“Tesaro” or the “Company”) (NASDAQ: TSRO) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Tesaro investigation page on our website www.glancylaw.com/case/tesaro-inc.
On January 12, 2018, Tesaro announced that it updated the U.S. labeling for Varubi (rolapitant), for the prevention of delayed nausea and vomiting associated with chemotherapy, after receiving reports of anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions in the postmarketing setting, some requiring hospitalization. The Company further disclosed that it “has issued a Dear Healthcare Professional (DHCP) letter.”
On this news, shares of Tesaro fell $9.80 or 13.7%, to close at $61.86 on January 17, 2018, thereby injuring investors.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased Tesaro, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.